Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Catalytic antibodies to HIV: physiological role and potential clinical utility.

Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S.

Autoimmun Rev. 2008 Jun;7(6):473-9. doi: 10.1016/j.autrev.2008.04.002. Epub 2008 Apr 29. Review.

2.

Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, Paul S.

J Immunol. 2012 Dec 1;189(11):5367-81. doi: 10.4049/jimmunol.1200981. Epub 2012 Oct 22.

3.

Structural basis of the gp120 superantigen-binding site on human immunoglobulins.

Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, Zouali M.

J Immunol. 1998 Dec 15;161(12):6681-8.

4.

Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit.

Nishiyama Y, Karle S, Planque S, Taguchi H, Paul S.

Mol Immunol. 2007 Apr;44(10):2707-18. Epub 2007 Jan 12.

PMID:
17222909
5.

Tracking immunoglobulin variable-gene expression in HIV infection.

Zouali M.

Appl Biochem Biotechnol. 2000 Jan-Mar;83(1-3):13-28; discussion 28-9, 145-53. Review.

PMID:
10826946
6.

Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection.

Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, Kyle R, Okhuysen P, Escobar M, Hunter R, Sheppard HW, Hanson C, Paul S.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1541-54.

PMID:
18160012
7.

Identification of the B cell superantigen-binding site of HIV-1 gp120.

Karray S, Zouali M.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1356-60.

8.

HIV-1 gp120: a novel viral B cell superantigen.

Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L.

Int Rev Immunol. 1997;14(4):325-38. Review.

PMID:
9186784
9.

Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.

Neshat MN, Goodglick L, Lim K, Braun J.

Int Immunol. 2000 Mar;12(3):305-12.

PMID:
10700465
10.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

11.

Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.

Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, Marasco WA.

Mol Immunol. 1994 Oct;31(15):1149-60.

PMID:
7935503
12.

Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.

Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, Handy B, Hunter R, Edmundson A, Hanson C.

J Biol Chem. 2004 Sep 17;279(38):39611-9. Epub 2004 Jul 21.

13.

Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Craig RB, Summa CM, Corti M, Pincus SH.

PLoS One. 2012;7(10):e46778. doi: 10.1371/journal.pone.0046778. Epub 2012 Oct 4.

14.

Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P.

PLoS One. 2011 Feb 23;6(2):e17253. doi: 10.1371/journal.pone.0017253.

15.

Mapping the Ig superantigen-binding site of HIV-1 gp120.

Goodglick L, Zevit N, Neshat MS, Braun J.

J Immunol. 1995 Dec 1;155(11):5151-9.

PMID:
7594524
17.

Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.

Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L.

AIDS Res Hum Retroviruses. 2003 Jul;19(7):597-607.

PMID:
12908937
18.

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A.

J Immunol. 2002 Jul 1;169(1):595-605.

19.

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection.

Juompan L, Lambin P, Zouali M.

FASEB J. 1998 Nov;12(14):1473-80.

PMID:
9806756
20.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

Supplemental Content

Support Center